0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > B7-2

B7-2

B7-2 Molecule Information

Name:Cluster of differentiation 86
Target Synonym:FUN-1?CTLA-4 counter-receptor B7.2?CD28LG2?Activation B7-2 antigen?CD86?CD86 Molecule?CD86 Antigen (CD28 Antigen Ligand 2? B7-2 Antigen)?BU63?B70?B-Lymphocyte Activation Antigen B7-2?T-Lymphocyte Activation Antigen CD86?B-Lymphocyte Antigen B7-2?CD86 Anti
Number of Launched Drugs:2
Number of Drugs in Clinical Trials:1
Lastest Research Phase:Approved

B7-2 Protein Product ListCompare or Buy

B7-2 Part of Bioactivity data

CD6-H82F5-Cell-based assay
FACS assay shows that recombinant Biotinylated FACS

Flow Cytometry assay shows that Biotinylated Human B7-2, Fc,Avitag (Cat. No. CD6-H82F5) can bind to CD28 expressed on Jurkat E6.1 cells. The concentration of B7-2 used is 1.5 μg/mL (Routinely tested).

CD6-H82F5-Cell-based assay
FACS assay shows that recombinant Biotinylated FACS

FACS analysis shows that the binding of Biotinylated Human B7-2, Fc,Avitag to CD28 expressed on Jurkat E6.1 was inhibited by increasing concentration of neutralizing Anti-CD28 antibody. The concentration of B7-2 used is 1.5 μg/mL. The IC50 is 0.031 μg/mL (Routinely tested).

CD6-C5254-BLI
Human_FcRn_Heterodimer_Protein_Bli

Loaded Cynomolgus / Rhesus macaque B7-2, Fc Tag (Cat. No. CD6-C5254) on Protein A Biosensor, can bind Human / Cynomolgus / Rhesus macaque CD28, His Tag (Cat. No. CD8-H52Hc) with an affinity constant of 11 μM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

CD6-H5223-BLI
Human_FcRn_Heterodimer_Protein_Bli

Loaded Human / Cynomolgus / Rhesus macaque CD28, Fc Tag (HPLC-verified) (Cat. No. CD8-H525a) on Protein A Biosensor, can bind Human B7-2, His Tag (Cat. No. CD6-H5223) with an affinity constant of 6.8 μM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

B7-2 Customer Reviews

B7-2 Molecule Synonym Name

CD86,B7-2,B70,CD28LG2,LAB72,MGC34413

B7-2 Molecule Background

Cluster of Differentiation 86 (CD86) is also known as B-lymphocyte activation antigen B7-2, is a type I membrane protein that is a member of the immunoglobulin superfamily, and is constitutively expressed on interdigitating dendritic cells, Langerhans cells, peripheral blood dendritic cells, memory B cells, and germinal center B cells. Additionally, B72 is expressed at low levels on monocytes and can be upregulated through interferon ¦Ã. CD86 is the ligand for two different proteins on the T cell surface: CD28 (for autoregulation and intercellular association) and CTLA-4 (for attenuation of regulation and cellular disassociation). CD86 works in tandem with CD80 to prime T cells. Recent study has revealed that B7-2 promotes the generation of a mature APC repertoire and promotes APC function and survival. Furthermore, the B7 proteins are also involved in innate immune responses by activating NF-¦ÊB-signaling pathway in macrophages. CD86 thus is regarded as a promising candidate for immune therapy. CD86+ macrophages in Hodgkin lymphoma patients are an independent marker for potential nonresponse to firstline-therapy.

B7-2 References

B7-2 Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Abatacept BMS-188667SC; ONO-4164; BMS-188667; ONO-4164SC Approved Bristol-Myers Squibb Company Orencia Mainland China Arthritis, Rheumatoid s:28:"Bristol-Myers Squibb Company"; 2005-12-23 Nephrosis, Lipoid; Crohn Disease; Nephrotic Syndrome; Muscular Diseases; Arthritis, Psoriatic; Colitis, Ulcerative; Glomerulosclerosis, Focal Segmental; Psoriasis; Lupus Erythematosus, Systemic; Polymyositis; Lupus Nephritis; Multiple Sclerosis; Arthritis, Juvenile; Coronavirus Disease 2019 (COVID-19); Sjogren's Syndrome; Arthritis, Rheumatoid; Dermatomyositis; Giant Cell Arteritis Details
Belatacept LEA29Y; LEA-029; BMS-224818; L104EA29YIg Approved Bristol-Myers Squibb Company Nulojix EU Rejection of renal transplantation s:32:"Bristol-Myers Squibb Pharma Eeig"; 2011-06-15 Rejection of renal transplantation; Rejection of organ transplantation Details

B7-2 Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Chimeric antigen receptor T-cell therapy (Hunan Zhaotai Yongren Biotech) Z-CTLs Phase 1 Clinical Hunan Zhaotai Yongren Biotech Carcinoma, Non-Small-Cell Lung Details

This web search service is supported by Google Inc.

totop